Results 171 to 180 of about 98,145 (299)

Anti-HCV NS2-3 potential of selected plant bioactive compounds revealed by docking, simulation and DFT. [PDF]

Sci Rep
Mboto CI, Mbim EN, Edet UO, Lugos M, Abdalla M, Ndifon WO, Ebenso EE, Udo SI, Egharevba HO, George UE, El-Sayed MH, Abdalla SF.   +11 more
europepmc   +1 more source

Seamless support from screening to anti-HCV treatment and HCC/ decompensated cirrhosis: Subsidy programs for HCV elimination. [PDF]

Glob Health Med, 2021
Setoyama H, Tanaka Y, Kanto T.
europepmc   +1 more source

Organoids: From Bench to Bedside Applications

MedComm, Volume 7, Issue 6, June 2026.
Organoids, as a groundbreaking biomedical research platform, utilize adult stem cells (ASCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) as sources. By integrating specific growth and differentiation signals within an extracellular matrix (e.g., Matrigel), organoids guide cells to self‐assemble into three‐dimensional ...
Kelin Li, Rui Cao, Maochen Li, Zichao Tian, Huahao Fan, Bixia Hong, Xiaojuan Liu   +6 more
wiley   +1 more source

The prevalence of hepatitis B infection and anti-HCV antibody in patients with diabetes mellitus. [PDF]

J Diabetes Investig
Naderi M, Hosseini SM, Hamidi V, Moradi A.   +3 more
europepmc   +1 more source

The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance. [PDF]

PLoS One, 2021
Bobardt M, Ramirez CM, Baum MM, Ure D, Foster R, Gallay PA.   +5 more
europepmc   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Pilot screening for anti-HCV in adults at the <i>Centre Médico-Chirurgical St-Damien</i> in Ambanja, Madagascar. [PDF]

Pan Afr Med J
De Maria F, Jinoro J, Vavisoa MV, Ampilaza MB, Ciccozzi M, Mottini G.   +5 more
europepmc   +1 more source

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. [PDF]

Signal Transduct Target Ther, 2021
Bai Y, Ye F, Feng Y, Liao H, Song H, Qi J, Gao GF, Tan W, Fu L, Shi Y.   +9 more
europepmc   +1 more source

Freeze‐Derived Microporous Biomaterials for Tissue Engineering Applications

Smart Medicine, Volume 5, Issue 3, June 2026.
Ice‐templating demonstrates significant potential to revolutionize tissue engineering through freeze‐induced microphase separation for fabricating hierarchical, biomimetic scaffolds. This review comprehensively examines recent advances in mechanisms and applications in tissue engineering, such as 3D cell culture, wound healing, bone regeneration, nerve
Shuangshuang Miao, Xingkui Guo, Chenhui Bai, Wei Zhou, Yiwen Wu, Wanchuan Ding, Jingjing Gan   +6 more
wiley   +1 more source

Effects of blood sample mishandling on anti-HCV IgG antibodies. [PDF]

Lancet Reg Health Am
Yang L, Wang Y, Zhao Y, Zhang F, Guo L, Yan X, Zhao J.   +6 more
europepmc   +1 more source